Cargando…

Aminochrome as preclinical model for Parkinson's disease

Detalles Bibliográficos
Autor principal:	Segura-Aguilar, Juan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542161/ https://www.ncbi.nlm.nih.gov/pubmed/28586763 http://dx.doi.org/10.18632/oncotarget.18353

Ejemplares similares

On the Role of Aminochrome in Mitochondrial Dysfunction and Endoplasmic Reticulum Stress in Parkinson's Disease
por: Segura-Aguilar, Juan
Publicado: (2019)

Aminochrome Induces Irreversible Mitochondrial Dysfunction by Inducing Autophagy Dysfunction in Parkinson's Disease
por: Segura-Aguilar, Juan, et al.
Publicado: (2018)

State and perspectives on flavonoid neuroprotection against aminochrome-induced neurotoxicity
por: Silva, Victor, et al.
Publicado: (2021)

Astrocytes protect dopaminergic neurons against aminochrome neurotoxicity
por: Segura-Aguilar, Juan, et al.
Publicado: (2022)

Neuroprotection against Aminochrome Neurotoxicity: Glutathione Transferase M2-2 and DT-Diaphorase
por: Segura-Aguilar, Juan, et al.
Publicado: (2022)

Can we conclude a potential therapeutic action for Parkinson’s disease by using postmortem tissue and a preclinical model based on an exogenous neurotoxin?
por: Segura-Aguilar, Juan
Publicado: (2018)

A Preclinical Model for Parkinson’s Disease Based on Transcriptional Gene Activation via KEAP1/NRF2 to Develop New Antioxidant Therapies
por: Segura-Aguilar, Juan, et al.
Publicado: (2023)

Commentary: Evaluation of Models of Parkinson's Disease
por: Muñoz, Patricia, et al.
Publicado: (2016)

Corrigendum: Commentary: Evaluation of Models of Parkinson's Disease
por: Muñoz, Patricia, et al.
Publicado: (2016)

Single-neuron neurodegeneration as a degenerative model for Parkinson’s disease
por: Huenchuguala, Sandro, et al.
Publicado: (2023)

On the role of endogenous neurotoxins and neuroprotection in Parkinson's disease
por: Segura-Aguilar, Juan
Publicado: (2017)

On the Role of Iron in Idiopathic Parkinson’s Disease
por: Huenchuguala, Sandro, et al.
Publicado: (2023)

Sleep and circadian rhythms in Parkinson’s disease and preclinical models
por: Hunt, Jeremy, et al.
Publicado: (2022)

Commentary: Gene Therapy: A Promising Approach for Neuroprotection in Parkinson's Disease?
por: Segura-Aguilar, Juan
Publicado: (2017)

Commentary: A Humanized Clinically Calibrated Quantitative Systems Pharmacology Model for Hypokinetic Motor Symptoms in Parkinson's Disease
por: Muñoz, Patricia, et al.
Publicado: (2016)

Animal Models of Parkinson's Disease
por: Imai, Yuzuru, et al.
Publicado: (2011)

Animal Models of Parkinson's Disease 2012
por: Imai, Yuzuru, et al.
Publicado: (2012)

Preclinical Modeling for Therapeutic Development in Cystic Fibrosis
por: Bonfield, Tracey L.
Publicado: (2020)

Preclinical Models: Boosting Synergies for Improved Translation
por: Attanasio, Chiara, et al.
Publicado: (2020)

Familial Parkinson's Disease/Parkinsonism
por: Tomiyama, Hiroyuki, et al.
Publicado: (2015)

Mitochondrial Dynamics and Mitophagy in the 6-Hydroxydopamine Preclinical Model of Parkinson's Disease
por: Galindo, Maria F., et al.
Publicado: (2012)

Double hit mouse model of Parkinson's disease
por: Schirinzi, Tommaso, et al.
Publicado: (2016)

Emerging preclinical pharmacological targets for Parkinson's disease
por: More, Sandeep Vasant, et al.
Publicado: (2016)

A novel preclinical model for rheumatoid arthritis research
por: Petersen, Frank, et al.
Publicado: (2010)

A preclinical model for phenogroup 3 HFpEF
por: Yousefi, Keyvan, et al.
Publicado: (2019)

Novel modeling methodologies for the neuropathological dimensions of Parkinson's disease
por: Vlamos, Panagiotis
Publicado: (2020)

People with Parkinson’s as Partners for the Journal of Parkinson’s Disease
por: McFarthing, Kevin, et al.
Publicado: (2023)

Enhanced Neuroprotective Effects of Coadministration of Tetrandrine with Glutathione in Preclinical Model of Parkinson's Disease
por: Li, Xiang-Yun, et al.
Publicado: (2015)

Evolution of 3D Cultures: Toward Tailored Preclinical Models
por: Benelli, Roberto, et al.
Publicado: (2023)

Advancing preclinical cancer models to assess clinically relevant outcomes
por: Golebiewska, Anna, et al.
Publicado: (2023)

Circuit imaging biomarkers in preclinical and prodromal Parkinson's disease
por: Meles, Sanne K., et al.
Publicado: (2021)

Rehabilitation and Parkinson's Disease
por: Earhart, Gammon M., et al.
Publicado: (2012)

Neuropsychiatry of Parkinson's Disease
por: Teixeira, Antonio L., et al.
Publicado: (2012)

Inflammation and Parkinson's Disease
por: Barcia, Carlos, et al.
Publicado: (2011)

Mitochondria and Parkinson's Disease
por: Simon, David K., et al.
Publicado: (2011)

Cannabidiol in Parkinson’s disease
por: Rieder, Carlos R.
Publicado: (2020)

Gait in Parkinson's Disease
por: Martinez-Ramirez, Daniel, et al.
Publicado: (2019)

Neurobiology of Parkinson’s Disease
por: Morelli, Micaela, et al.
Publicado: (2023)

ABC Transporters: An Overlooked Mechanism of Drug Failure in Our Preclinical Models?
por: Redente, Elizabeth F.
Publicado: (2020)

Back to the future through the wormhole: Caenorhabditis elegans as a preclinical model
por: Caldwell, Guy A.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dt52bpim5cml0tkn1kpknqolru